FMP
Jun 18, 2025 2:00 PM - Andrew Wynn
Image credit: Google Images
Aurora Cannabis Inc. (NASDAQ: ACB, TSX: ACB) is a leading global medical cannabis company based in Canada. It focuses on producing and distributing medical cannabis products worldwide. Aurora competes with other major players in the cannabis industry, such as Tilray and Canopy Growth. Despite facing challenges, Aurora is making strides towards profitability through strategic shifts and financial management.
On June 18, 2025, Aurora reported an earnings per share (EPS) of -$0.24, missing the estimated EPS of $0.11. Aurora's actual revenue of approximately $63.3 million was below the estimated $88.9 million.
Aurora's financial metrics reveal a mixed picture. The company has a price-to-earnings (P/E) ratio of approximately 41.17, indicating investor confidence in its future earnings potential. However, the enterprise value to operating cash flow ratio is negative at -40.01, suggesting challenges in generating positive cash flow from operations. Despite this, Aurora maintains a strong liquidity position with a current ratio of 3.30, indicating its ability to meet short-term obligations.
Nov 22, 2024 5:08 AM - Parth Sanghvi
Fundamental analysis is one of the most essential tools for investors and analysts alike, helping them assess the intrinsic value of a stock, company, or even an entire market. It focuses on the financial health and economic position of a company, often using key data such as earnings, expenses, ass...
Dec 17, 2024 8:58 AM - Sanzhi Kobzhan
Tesla, one of the world’s most talked-about electric vehicle manufacturers, attracts a lot of attention from investors and market watchers. By examining a snapshot of Tesla’s financial ratios—such as those provided by FinancialModelingPrep’s Ratios API—we can get a clearer picture of the company’s f...
Dec 22, 2024 7:59 AM - Sanzhi Kobzhan
When it comes to cutting-edge software and data analytics, Palantir Technologies (NYSE: PLTR) is often front and center. But for many investors, it’s important to consider alternative or complementary stocks in the same sector that may offer robust growth potential. As PLTR looks expensive (overvalu...